Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts rate Inspire Medical Systems “Hold” overall: Of 19 firms, 11 recommend holding, three rate it a sell, three a buy, and two a strong buy. The average 12-month price target is $66.19, though targets range from $39 to $85.
• Recent results exceeded expectations but showed weaker growth: Inspire reported quarterly EPS of $0.14 versus the expected loss of $0.24 and revenue of $200.58 million versus estimates of $194.72 million, while revenue declined 7.6% year over year.
• The stock remains volatile and institutionally held: INSP opened at $62.99, compared with a 12-month range of $38.91 to $147.03, while institutional investors own 94.91% of shares. An insider recently sold 963 shares at an average price of $59.55.

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) have received a consensus recommendation of "Hold" from the nineteen research firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $66.1875.

Several equities analysts have recently commented on INSP shares. Weiss Ratings lowered Inspire Medical Systems from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday. UBS Group initiated coverage on Inspire Medical Systems in a research note on Tuesday, July 28th. They set a "sell" rating and a $39.00 price target for the company. Oppenheimer raised shares of Inspire Medical Systems from a "market perform" rating to an "outperform" rating and set a $85.00 price objective on the stock in a research note on Tuesday, August 4th. Bank of America lowered Inspire Medical Systems from a "neutral" rating to an "underperform" rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. Finally, Evercore set a $54.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, August 4th.

Inspire Medical Systems Price Performance

INSP opened at $62.99 on Friday. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 4.79 and a beta of 0.70. The business has a 50-day moving average of $55.05 and a two-hundred day moving average of $52.43. Inspire Medical Systems has a 12 month low of $38.91 and a 12 month high of $147.03.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to analysts' expectations of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm's quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities research analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Jason Kelly sold 963 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by company insiders.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC raised its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after acquiring an additional 242 shares during the last quarter. Havemeyer Place LP acquired a new position in Inspire Medical Systems during the 4th quarter worth $39,000. Smartleaf Asset Management LLC boosted its position in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after purchasing an additional 130 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company's stock valued at $33,000 after purchasing an additional 580 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source